New international treatment guidelines issued in July 2020 recommend the use of ARIKAYCE in combination with a multidrug regimen in patients with MAC lung disease who have failed standard therapy ...

On Thursday, AN2 Therapeutics, Inc. (NASDAQ:ANTX) released topline results from the Phase 2 part of the EBO-301 Phase 2/3 study of epetraborole on top of an optimized background regimen (OBR) in ...

Insmed Incorporated (INSM) is in a good position as a pharmaceutical company. It has already received regulatory approval in several territories for its drug known as ARIKAYCE which has been approved ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

About MAC Lung Disease Mycobacterium avium complex (MAC) lung disease is a rare and serious disorder that can significantly increase morbidity and mortality. Patients with MAC lung disease can ...

—Patients Treated with ARIKAYCE Plus Macrolide-Based Background Regimen Had Meaningfully Greater Improvements in Respiratory Symptoms vs. Macrolide-Based Background Regimen Alone, As Measured By the ...

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron ...

Concerns of lower-than-expected efficacy, which prompted AN2 Therapeutics Inc. to pause enrollment in the phase III portion of the phase II/III trial earlier this year, turned out to be well-founded, ...

Dear Doctors: I suffered extensive fatigue that I had attributed to a COVID-19 infection. Then a lung culture found something called mycobacterium avium complex. Would you kindly consider discussing ...

Shares of Insmed climbed after the company disclosed what it called positive topline results from a late-stage study of its treatment for certain lung infections. The stock rose 10%, to $150.02, in ...

Goal to Accelerate Unblinding Phase 3 Data in Q2 2025 Ahead of Potential FDA Meeting MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on ...

Dear Doctors: I suffered extensive fatigue that I had attributed to a COVID-19 infection. Then a lung culture found something called mycobacterium avium complex. Would you kindly consider discussing ...